Biotest GmbH KGaA (LTS:0N6Z) EBIT: £ Mil (TTM As of . 20)


What is Biotest GmbH KGaA EBIT?

Biotest GmbH KGaA LTS:0N6Z EBIT is £ Mil as of . 20.

Biotest GmbH KGaA's earnings before interest and taxes (EBIT) for the six months ended in . 20 was £0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Biotest GmbH KGaA  (LTS:0N6Z) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biotest GmbH KGaA's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is one times the annual (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

Biotest GmbH KGaA's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (. 20) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biotest GmbH KGaA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: . 20 )
=/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest GmbH KGaA EBIT Related Terms

Biotest GmbH KGaA EBIT Historical Data

* Premium members only.

The historical data trend for Biotest GmbH KGaA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest GmbH KGaA EBIT Chart

Biotest GmbH KGaA Annual Data
Trend
EBIT

Biotest GmbH KGaA Semi-Annual Data
EBIT

LTS:0N6Z vs : EBIT Comparison

For the Biotechnology subindustry, Biotest GmbH KGaA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotest GmbH KGaA EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest GmbH KGaA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biotest GmbH KGaA's EV-to-EBIT falls into.


Biotest GmbH KGaA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in . 20 was £ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of £ Mil mean?
Biotest GmbH KGaA (LTS:0N6Z) has a EBIT of £ Mil as of . 20. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biotest GmbH KGaA.
Is Biotest GmbH KGaA's EBIT too high?
Biotest GmbH KGaA's current EBIT is £ Mil.
How does Biotest GmbH KGaA's EBIT compare to ?
Biotest GmbH KGaA's EBIT of £ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biotest GmbH KGaA. Biotest GmbH KGaA's current EBIT is £ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest GmbH KGaA stock overvalued right now?
Biotest GmbH KGaA (LTS:0N6Z) has a current EBIT of £ Mil. The current EBIT is £ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Biotest GmbH KGaA (LTS:0N6Z), the current EBIT is £ Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest GmbH KGaA Business Description

Comparable Companies
Biotest GmbH & Co KGaA is a specialist in haematology, clinical immunology, and intensive care medicine. The group develops, manufactures, and markets plasma proteins and biotherapeutic drugs. The group's value chain extends from pre-clinical and clinical development to world-wide marketing and distribution. It manufactures immunoglobulins, clotting factors, and albumins, which are derived from human blood plasma. The group markets its products in Europe, the Middle East, China, Australia, Africa, and the USA.